coumarin has been researched along with Neoplasms in 52 studies
2H-chromen-2-one: coumarin derivative
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding." | 9.30 | Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. ( Abreu, P; Carrier, M; Feugère, G; Heissler, J; Lee, AYY; Woodruff, S, 2019) |
| "Survival data were examined in a posthoc analysis in patients with solid tumors and venous thromboembolism who were randomly assigned to dalteparin or a coumarin derivative for 6 months in a multicenter, open-label, randomized, controlled trial." | 9.11 | Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. ( Baker, RI; Bowden, C; Gent, M; Julian, JA; Kakkar, AK; Lee, AY; Levine, MN; Prins, M; Rickles, FR, 2005) |
| "In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding." | 5.30 | Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. ( Abreu, P; Carrier, M; Feugère, G; Heissler, J; Lee, AYY; Woodruff, S, 2019) |
| "Survival data were examined in a posthoc analysis in patients with solid tumors and venous thromboembolism who were randomly assigned to dalteparin or a coumarin derivative for 6 months in a multicenter, open-label, randomized, controlled trial." | 5.11 | Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. ( Baker, RI; Bowden, C; Gent, M; Julian, JA; Kakkar, AK; Lee, AY; Levine, MN; Prins, M; Rickles, FR, 2005) |
| "By identifying VTE recurrence risk in cancer patients with VTE, we may be able to tailor treatment, improving clinical outcomes while minimizing costs." | 2.77 | Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. ( Carrier, M; Dao, V; Kovacs, MJ; Lazo-Langner, A; Lee, AY; Louzada, ML; Meyer, G; Ramsay, TO; Rodger, MA; Wells, PS; Zhang, J, 2012) |
| "Coumarin is a relatively nontoxic, oral, outpatient therapy that warrants further investigations for the treatment of human malignancies." | 2.67 | Phase I evaluation of coumarin (1,2-benzopyrone) and cimetidine in patients with advanced malignancies. ( Butler, K; Fried, A; Marshall, ME, 1991) |
| "The anticancer agents play an intriguing role in the treatment of cancers, while the severe anticancer scenario and the emergence of drug-resistant especially multidrug-resistant cancers create a huge demand for novel anticancer drugs with different mechanisms of action." | 2.61 | Coumarin-containing hybrids and their anticancer activities. ( Xu, Z; Zhang, L, 2019) |
| " Bioavailability evidence of closely related structural monomers could be applicable to their dimeric forms." | 2.61 | Natural dimers of coumarin, chalcones, and resveratrol and the link between structure and pharmacology. ( Diederich, MF; Menezes, JCJMDS, 2019) |
| "However, due to heterogeneity of cancer, the search is still on to develop drugs for specific types of cancers." | 2.52 | Coumarin: a promising scaffold for anticancer agents. ( Bansal, G; Bansal, Y; Kaur, M; Kohli, S; Sandhu, S, 2015) |
| "Despite substantial research on cancer therapeutics, systemic toxicity and drug-resistance limits the clinical application of many drugs like cisplatin." | 1.46 | Synthesis of novel coumarin nucleus-based DPA drug-like molecular entity: In vitro DNA/Cu(II) binding, DNA cleavage and pro-oxidant mechanism for anticancer action. ( Khan, S; Malla, AM; Naseem, I; Zafar, A, 2017) |
| "To promote cancer cell targeting with high-specificity, the nanoprobes are also conjugated with folic acid to establish a greater affinity for cancer cells that over-express folate receptors on their cell membrane." | 1.43 | pH-Activatable MnO-Based Fluorescence and Magnetic Resonance Bimodal Nanoprobe for Cancer Imaging. ( Bhakoo, K; Connell, J; Hsu, BY; Li, X; Lythgoe, M; Ng, M; Roberts, T; Seifalian, AM; Tan, A; Wang, J; Wong, SY; Zhang, Y, 2016) |
| "A novel cancer targeting and pH-responsive prodrug was successfully designed and synthesized." | 1.40 | A pH-responsive prodrug for real-time drug release monitoring and targeted cancer therapy. ( Cheng, H; Jia, HZ; Li, SY; Liu, LH; Qiu, WX; Rong, L; Zhang, XZ, 2014) |
| " An in vivo study demonstrated enhanced bioavailability of rapamycin in cubic NP in comparison with native rapamycin in a mouse model with no toxicity and good biocompatibility of void cubic NP at a higher dose of oral administration." | 1.37 | Enhanced cellular uptake and in vivo pharmacokinetics of rapamycin-loaded cubic phase nanoparticles for cancer therapy. ( Mohanty, C; Parhi, P; Sahoo, SK, 2011) |
| "Toxic gangrene is most commonly caused by extravasation of intravenously administered cytotoxic antineoplastic drugs but has also been associated with the use of coumarin congeners and the bite of the brown recluse spider." | 1.27 | Necrotizing dermatitis in patients receiving cancer chemotherapy. ( Bodey, GP; Dreizen, S; Keating, MJ; McCredie, KB, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (9.62) | 18.7374 |
| 1990's | 3 (5.77) | 18.2507 |
| 2000's | 3 (5.77) | 29.6817 |
| 2010's | 38 (73.08) | 24.3611 |
| 2020's | 3 (5.77) | 2.80 |
| Authors | Studies |
|---|---|
| Maresca, A | 4 |
| Supuran, CT | 5 |
| Scozzafava, A | 3 |
| Carta, F | 2 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 2 |
| Hitosugi, T | 1 |
| Zhang, L | 2 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 2 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 2 |
| Xu, Z | 1 |
| Shreevatsa, B | 1 |
| Dharmashekara, C | 1 |
| Swamy, VH | 1 |
| Gowda, MV | 1 |
| Achar, RR | 1 |
| Kameshwar, VH | 1 |
| Thimmulappa, RK | 1 |
| Syed, A | 1 |
| Elgorban, AM | 1 |
| Al-Rejaie, SS | 1 |
| Ortega-Castro, J | 1 |
| Frau, J | 1 |
| Flores-Holguín, N | 1 |
| Shivamallu, C | 1 |
| Kollur, SP | 1 |
| Glossman-Mitnik, D | 1 |
| Menezes, JCJMDS | 1 |
| Diederich, MF | 1 |
| Zhu, J | 1 |
| Song, D | 1 |
| Zhang, W | 1 |
| Guo, J | 1 |
| Cai, G | 1 |
| Ren, Y | 1 |
| Wan, C | 1 |
| Kong, L | 1 |
| Yu, W | 1 |
| Bhattarai, N | 1 |
| Kumbhar, AA | 1 |
| Pokharel, YR | 1 |
| Yadav, PN | 1 |
| Li, B | 1 |
| Liu, P | 1 |
| Wu, H | 1 |
| Xie, X | 1 |
| Chen, Z | 1 |
| Zeng, F | 1 |
| Khan, S | 1 |
| Malla, AM | 1 |
| Zafar, A | 1 |
| Naseem, I | 1 |
| Cuff, S | 1 |
| Lewis, RD | 1 |
| Chinje, E | 1 |
| Jaffar, M | 1 |
| Knox, R | 1 |
| Weeks, I | 1 |
| Wang, H | 1 |
| Miao, W | 1 |
| Wang, F | 1 |
| Cheng, Y | 1 |
| An, R | 1 |
| Hou, Z | 1 |
| Li, JT | 1 |
| Yu, HN | 1 |
| Mou, YH | 1 |
| Guo, C | 2 |
| Woodruff, S | 1 |
| Lee, AYY | 1 |
| Carrier, M | 2 |
| Feugère, G | 1 |
| Abreu, P | 1 |
| Heissler, J | 1 |
| Novohradsky, V | 1 |
| Rovira, A | 1 |
| Hally, C | 1 |
| Galindo, A | 1 |
| Vigueras, G | 1 |
| Gandioso, A | 2 |
| Svitelova, M | 1 |
| Bresolí-Obach, R | 1 |
| Kostrhunova, H | 1 |
| Markova, L | 1 |
| Kasparkova, J | 1 |
| Nonell, S | 1 |
| Ruiz, J | 1 |
| Brabec, V | 1 |
| Marchán, V | 1 |
| Maiti, S | 2 |
| Park, N | 1 |
| Han, JH | 1 |
| Jeon, HM | 1 |
| Lee, JH | 3 |
| Bhuniya, S | 1 |
| Kang, C | 1 |
| Kim, JS | 2 |
| Zou, Q | 1 |
| Fang, Y | 1 |
| Zhao, Y | 1 |
| Zhao, H | 1 |
| Wang, Y | 1 |
| Gu, Y | 2 |
| Wu, F | 1 |
| Chen, H | 1 |
| Li, S | 1 |
| Yao, Y | 1 |
| Zhao, J | 1 |
| Wang, K | 1 |
| Li, X | 2 |
| Arcau, J | 1 |
| Andermark, V | 1 |
| Aguiló, E | 1 |
| Moro, A | 1 |
| Cetina, M | 1 |
| Lima, JC | 1 |
| Rissanen, K | 1 |
| Ott, I | 1 |
| Rodríguez, L | 1 |
| Jung, D | 1 |
| Leung, EY | 1 |
| Tirlapur, SA | 1 |
| Meads, C | 1 |
| Li, SY | 1 |
| Liu, LH | 1 |
| Jia, HZ | 1 |
| Qiu, WX | 1 |
| Rong, L | 1 |
| Cheng, H | 1 |
| Zhang, XZ | 1 |
| Liu, MM | 1 |
| Chen, XY | 1 |
| Huang, YQ | 1 |
| Feng, P | 1 |
| Guo, YL | 1 |
| Yang, G | 1 |
| Chen, Y | 1 |
| Li, H | 1 |
| Mu, Y | 1 |
| Qian, S | 1 |
| Lu, J | 1 |
| Wan, Y | 1 |
| Fu, G | 1 |
| Liu, S | 1 |
| Kaur, M | 1 |
| Kohli, S | 1 |
| Sandhu, S | 1 |
| Bansal, Y | 1 |
| Bansal, G | 1 |
| Jiang, Z | 1 |
| Yang, J | 1 |
| Pang, Y | 1 |
| Yang, X | 1 |
| Yu, S | 1 |
| Jia, L | 1 |
| Patil, R | 1 |
| Sawant, S | 1 |
| Mohareb, RM | 1 |
| MegallyAbdo, NY | 1 |
| Hsu, BY | 1 |
| Ng, M | 1 |
| Tan, A | 1 |
| Connell, J | 1 |
| Roberts, T | 1 |
| Lythgoe, M | 1 |
| Zhang, Y | 1 |
| Wong, SY | 1 |
| Bhakoo, K | 1 |
| Seifalian, AM | 1 |
| Wang, J | 1 |
| Tian, Y | 1 |
| Liang, Z | 1 |
| Xu, H | 1 |
| Mou, Y | 1 |
| Vicari, L | 1 |
| Musumeci, T | 1 |
| Giannone, I | 1 |
| Adamo, L | 1 |
| Conticello, C | 1 |
| De Maria, R | 1 |
| Pignatello, R | 1 |
| Puglisi, G | 1 |
| Gulisano, M | 1 |
| Das, M | 1 |
| Sahoo, SK | 2 |
| Valente, S | 1 |
| Bana, E | 1 |
| Viry, E | 1 |
| Bagrel, D | 1 |
| Kirsch, G | 1 |
| Parhi, P | 1 |
| Mohanty, C | 1 |
| Khoobi, M | 1 |
| Foroumadi, A | 1 |
| Emami, S | 1 |
| Safavi, M | 1 |
| Dehghan, G | 1 |
| Alizadeh, BH | 1 |
| Ramazani, A | 1 |
| Ardestani, SK | 1 |
| Shafiee, A | 1 |
| Huang, XY | 1 |
| Shan, ZJ | 1 |
| Zhai, HL | 1 |
| Su, L | 1 |
| Zhang, XY | 1 |
| Iangcharoen, P | 1 |
| Punfa, W | 1 |
| Yodkeeree, S | 1 |
| Kasinrerk, W | 1 |
| Ampasavate, C | 1 |
| Anuchapreeda, S | 1 |
| Limtrakul, P | 1 |
| Louzada, ML | 1 |
| Lazo-Langner, A | 1 |
| Dao, V | 1 |
| Kovacs, MJ | 1 |
| Ramsay, TO | 1 |
| Rodger, MA | 1 |
| Zhang, J | 1 |
| Lee, AY | 2 |
| Meyer, G | 1 |
| Wells, PS | 1 |
| Raunio, H | 1 |
| Rahnasto-Rilla, M | 1 |
| MANNA, GK | 1 |
| GOODMAN, DH | 1 |
| PATHAK, MA | 1 |
| DANIELS, F | 1 |
| HOPKINS, CE | 1 |
| FITZPATRICK, TB | 1 |
| Rickles, FR | 1 |
| Julian, JA | 1 |
| Gent, M | 1 |
| Baker, RI | 1 |
| Bowden, C | 1 |
| Kakkar, AK | 1 |
| Prins, M | 1 |
| Levine, MN | 1 |
| Sas, G | 1 |
| Fernandez-Salguero, P | 1 |
| Gonzalez, FJ | 1 |
| Marshall, ME | 2 |
| Butler, K | 1 |
| Fried, A | 1 |
| Nagao, M | 1 |
| Nakayasu, M | 1 |
| Aonuma, S | 1 |
| Shima, H | 1 |
| Sugimura, T | 1 |
| Riley, LK | 1 |
| Rhoades, J | 1 |
| Eichhorn, T | 1 |
| Jennings, CD | 1 |
| Cibull, M | 1 |
| Thompson, J | 1 |
| Dreizen, S | 1 |
| McCredie, KB | 1 |
| Bodey, GP | 1 |
| Keating, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Analysis of Pro-coagulant and Thrombin-generation Markers for the Prediction of Therapeutic Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism: A Pilot Study[NCT01602445] | 700 participants (Anticipated) | Observational | 2012-07-31 | Completed | |||
| Randomized, Phase III-b, Multi-centre, Open-label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-oesophageal Cancer[NCT00718354] | Phase 3 | 740 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for coumarin and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Coumarin-containing hybrids and their anticancer activities.
Topics: Animals; Antineoplastic Agents; Coumarins; Drug Design; Drug Discovery; Humans; Neoplasms; Structure | 2019 |
Natural dimers of coumarin, chalcones, and resveratrol and the link between structure and pharmacology.
Topics: Antineoplastic Agents, Phytogenic; Biological Products; Chalcones; Coumarins; Dimerization; DNA Topo | 2019 |
Coumarin carbonic anhydrase inhibitors from natural sources.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Products; Carbonic Anhydrase Inhibitors; Carb | 2020 |
Anticancer Potential of Coumarin and its Derivatives.
Topics: Anti-Infective Agents; Antineoplastic Agents; Coumarins; Humans; Neoplasms | 2021 |
The management of secondary lower limb lymphoedema in cancer patients: a systematic review.
Topics: Coumarins; Disease Management; Humans; Lower Extremity; Lymphedema; Neoplasms; Palliative Medicine; | 2015 |
Coumarin: a promising scaffold for anticancer agents.
Topics: Animals; Antineoplastic Agents; Biological Products; Coumarins; Humans; Neoplasms; Signal Transducti | 2015 |
CYP2A6: genetics, structure, regulation, and function.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Coumarins; Cytochrome P-450 CYP2A6; Enzyme Inhibitors; Gene | 2012 |
[Old burdens and new perspectives of the long-term anticoagulant therapy].
Topics: Anticoagulants; Azetidines; Benzylamines; Coumarins; Drug Administration Schedule; Hemorrhage; Hepar | 2006 |
The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis.
Topics: Animals; Carcinogens; Cattle; Chromosome Mapping; Chromosomes, Human, Pair 19; Coumarins; Cricetinae | 1995 |
4 trials available for coumarin and Neoplasms
| Article | Year |
|---|---|
Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.
Topics: Aged; Coumarins; Dalteparin; Disease-Free Survival; Female; Hemorrhage; Humans; Male; Middle Aged; N | 2019 |
Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism.
Topics: Anticoagulants; Cohort Studies; Coumarins; Decision Support Techniques; Female; Heparin, Low-Molecul | 2012 |
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Coumarins; Dalteparin; Female; Heparin, L | 2005 |
Phase I evaluation of coumarin (1,2-benzopyrone) and cimetidine in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Coumarins; Dose-Response Re | 1991 |
38 other studies available for coumarin and Neoplasms
| Article | Year |
|---|---|
Coumarins incorporating hydroxy- and chloro-moieties selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II.
Topics: Antigens, Neoplasm; Binding Sites; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase I | 2010 |
7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range.
Topics: Antigens, Neoplasm; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Carb | 2010 |
5- and 6-membered (thio)lactones are prodrug type carbonic anhydrase inhibitors.
Topics: Antineoplastic Agents; Carbonic Anhydrase Inhibitors; Chemistry, Pharmaceutical; Coumarins; Drug Des | 2012 |
Novel coumarins and 2-thioxo-coumarins as inhibitors of the tumor-associated carbonic anhydrases IX and XII.
Topics: Antigens, Neoplasm; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Couma | 2012 |
Virtual Screening for Potential Phytobioactives as Therapeutic Leads to Inhibit NQO1 for Selective Anticancer Therapy.
Topics: Antineoplastic Agents; Antioxidants; Binding Sites; Coumarins; Flavones; Flavonoids; Humans; NAD(P)H | 2021 |
Real-time monitoring of etoposide prodrug activated by hydrogen peroxide with improved safety.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Coumarins; Drug Liberat | 2019 |
A bioorthogonal nanosystem for imaging and in vivo tumor inhibition.
Topics: Animals; Antineoplastic Agents; Coumarins; Ferrous Compounds; Fluorescent Dyes; HeLa Cells; Humans; | 2017 |
Synthesis of novel coumarin nucleus-based DPA drug-like molecular entity: In vitro DNA/Cu(II) binding, DNA cleavage and pro-oxidant mechanism for anticancer action.
Topics: Amines; Animals; Antineoplastic Agents; Binding, Competitive; Cell Line, Tumor; Cell Nucleus; Chelat | 2017 |
An improved cell-permeable fluorogenic substrate as the basis for a highly sensitive test for NAD(P)H quinone oxidoreductase 1 (NQO1) in living cells.
Topics: Biomarkers; Cell Line, Tumor; Cell Membrane; Cell Membrane Permeability; Coumarins; Fluorescent Dyes | 2018 |
A Self-Assembled Coumarin-Anchored Dendrimer for Efficient Gene Delivery and Light-Responsive Drug Delivery.
Topics: Antineoplastic Agents; Cell Line, Tumor; Coumarins; Dendrimers; Drug Delivery Systems; Fluorouracil; | 2018 |
Design, Synthesis and Biological Evaluation of Novel 4-Substituted Coumarin Derivatives as Antitumor Agents.
Topics: Antineoplastic Agents; Carbonic Anhydrase Inhibitors; Cell Line, Tumor; Cell Proliferation; Coumarin | 2018 |
Towards Novel Photodynamic Anticancer Agents Generating Superoxide Anion Radicals: A Cyclometalated Ir
Topics: Antineoplastic Agents; Cell Hypoxia; Cell Survival; Coordination Complexes; Coumarins; HeLa Cells; H | 2019 |
Gemcitabine-coumarin-biotin conjugates: a target specific theranostic anticancer prodrug.
Topics: Antineoplastic Agents; Biotin; Cell Line, Tumor; Cell Survival; Coumarins; Deoxycytidine; Drug Deliv | 2013 |
Synthesis and in vitro photocytotoxicity of coumarin derivatives for one- and two-photon excited photodynamic therapy.
Topics: Cell Survival; Coumarins; Hep G2 Cells; Humans; Models, Chemical; Molecular Structure; Neoplasms; Ph | 2013 |
Design, synthesis, and anti-tumor activities of novel triphenylethylene-coumarin hybrids, and their interactions with Ct-DNA.
Topics: Animals; Antineoplastic Agents; Cattle; Cell Line, Tumor; Cell Proliferation; Coumarins; DNA; Drug D | 2013 |
Luminescent alkynyl-gold(I) coumarin derivatives and their biological activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Coumarins; Crystallography, X-Ray; Drug Screening Assays, A | 2014 |
Rational design of biotin-disulfide-coumarin conjugates: a cancer targeted thiol probe and bioimaging.
Topics: Biotin; Cell Line, Tumor; Coumarins; Disulfides; Endocytosis; Fluorescent Dyes; Humans; Molecular Pr | 2014 |
A pH-responsive prodrug for real-time drug release monitoring and targeted cancer therapy.
Topics: Antineoplastic Agents; Cell Survival; Coumarins; Doxorubicin; Drug Delivery Systems; HeLa Cells; Hum | 2014 |
Hybrids of phenylsulfonylfuroxan and coumarin as potent antitumor agents.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinogenesis; Cell Cycle; Cell | 2014 |
Synthesis of fluorescent dye-doped silica nanoparticles for target-cell-specific delivery and intracellular microRNA imaging.
Topics: Aptamers, Nucleotide; Cell Line, Tumor; Coumarins; Diagnostic Imaging; Fluorescent Dyes; Humans; MCF | 2015 |
Bioactivity-guided fast screen and identification of cancer metastasis chemopreventive components from raw extracts of Murraya exotica.
Topics: Cell Line, Tumor; Chemoprevention; Chromatography, High Pressure Liquid; Coumarins; HT29 Cells; Huma | 2015 |
Molecular Dynamics Guided Receptor Independent 4D QSAR Studies of Substituted Coumarins as Anticancer Agents.
Topics: Antineoplastic Agents; Coumarins; Drug Design; Humans; Least-Squares Analysis; Mitogen-Activated Pro | 2015 |
Uses of 3-(2-Bromoacetyl)-2H-chromen-2-one in the Synthesis of Heterocyclic Compounds Incorporating Coumarin: Synthesis, Characterization and Cytotoxicity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Coumarins; Drug Screening Assays, Antit | 2015 |
pH-Activatable MnO-Based Fluorescence and Magnetic Resonance Bimodal Nanoprobe for Cancer Imaging.
Topics: Cell Line, Tumor; Cell Survival; Contrast Media; Coumarins; HeLa Cells; Humans; Hydrogen-Ion Concent | 2016 |
Design, Synthesis and Cytotoxicity of Novel Dihydroartemisinin-Coumarin Hybrids via Click Chemistry.
Topics: Antigens, Neoplasm; Artemisinins; Carbonic Anhydrase IX; Cell Proliferation; Click Chemistry; Coumar | 2016 |
Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromatograp | 2008 |
Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy.
Topics: Antigens, Neoplasm; Blotting, Western; Cell Adhesion Molecules; Cell Cycle; Cell Death; Cell Line, T | 2011 |
Synthesis and biological evaluation of novel coumarin-based inhibitors of Cdc25 phosphatases.
Topics: Antineoplastic Agents; cdc25 Phosphatases; Coumarins; Enzyme Inhibitors; Humans; Neoplasms | 2010 |
Enhanced cellular uptake and in vivo pharmacokinetics of rapamycin-loaded cubic phase nanoparticles for cancer therapy.
Topics: Animals; Apoptosis; Biocompatible Materials; Blotting, Western; Cell Line, Tumor; Chemical Phenomena | 2011 |
Coumarin-based bioactive compounds: facile synthesis and biological evaluation of coumarin-fused 1,4-thiazepines.
Topics: Antineoplastic Agents; Antioxidants; Cell Line, Tumor; Cell Survival; Chemistry Techniques, Syntheti | 2011 |
Study on the anticancer activity of coumarin derivatives by molecular modeling.
Topics: Antineoplastic Agents; Casein Kinase II; Coumarins; Drug Design; Enzyme Inhibitors; Humans; Models, | 2011 |
Anti-P-glycoprotein conjugated nanoparticles for targeting drug delivery in cancer treatment.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Ch | 2011 |
Handling human chromosomes by a coumarin technic.
Topics: Chromosomes; Chromosomes, Human; Coumarins; Humans; Neoplasms | 1956 |
Early clue to visceral carcinoma-hemorrhage after intravenously given warfarin.
Topics: Coumarins; Hemorrhage; Humans; Neoplasms; Warfarin | 1958 |
Ultra-violet carcinogenesis in albino and pigmented mice receiving furocoumarins: psoralen and 8-methoxypsoralen.
Topics: Animals; Carcinogenesis; Coumarins; Ficusin; Furans; Furocoumarins; Methoxsalen; Mice; Neoplasms; Ne | 1959 |
Loss of amplified genes by poly(ADP-ribose) polymerase inhibitors.
Topics: 3T3 Cells; Aminobenzoates; Animals; Benzamides; Benzoates; Benzoic Acid; Cell Differentiation; Cell | 1991 |
Effects of coumarin (1,2-benzopyrone) and cimetidine on peripheral blood lymphocytes, natural killer cells, and monocytes in patients with advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Cimetidine; Coumarins; Female; Humans; Killer Cells, Natural; Lympho | 1989 |
Necrotizing dermatitis in patients receiving cancer chemotherapy.
Topics: Antineoplastic Agents; Bacterial Infections; Cellulitis; Coumarins; Dermatitis; Female; Gangrene; Hu | 1987 |